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The rat conditioned avoidance response model is a well-established preclinical behavioral model predictive of antipsychotic
efficacy. All clinically approved antipsychotic drugs disrupt conditioned avoidance responding – a feature that distinguishes
them from other psychotherapeutics. We previously showed that the typical antipsychotic drug haloperidol disrupts avoidance
responding by progressively attenuating the motivational salience of the conditioned stimulus (CS) in normal rats. In this study,
using two pharmacological rat models of schizophrenia [e.g. phencyclidine (PCP) or amphetamine sensitization], we examined whether atypicals such as olanzapine or risperidone disrupt avoidance responding through the same behavioral mechanism. Rats were first pretreated with PCP, amphetamine, or saline under one of two different injection schedules for either 1 or
3 weeks. They were then trained to acquire avoidance responding to two types of CS (CS1 and CS2) that differed in their ability
to predict the occurrence of the unconditioned stimulus. Finally, rats were tested repeatedly under olanzapine (1.0 mg/kg, subcutaneously) or risperidone (0.33 mg/kg, subcutaneously) daily for 5 or 7 consecutive days. We found that repeated olanzapine
or risperidone treatment produced a progressive across-session decline in avoidance responding to both CS1 and CS2. Olanzapine and risperidone disrupted the CS2 (a less salient CS) avoidance to a greater extent than the CS1 avoidance. Pretreatment with
PCP and amphetamine did not affect the disruptive effect of olanzapine or risperidone on avoidance responding. On the basis
of these findings, we suggest that the atypical drugs olanzapine and risperidone, like the typical drug haloperidol, also disrupt
avoidance responding primarily by attenuating the motivational salience of the CS.

Introduction
The rat conditioned avoidance response (CAR) is an aversively motivated conditioned instrumental response in
which animals are trained to make an active motor response
to avoid footshock. In a typical CAR experiment, a rat is
placed in a two-compartment shuttle box and presented with
a conditioned stimulus (CS, e.g. white noise), followed by an
aversive unconditioned stimulus (US, e.g. footshock). After
several CS–US pairings, the rat typically runs from one compartment to another during the CS (before the onset of the
US), hence, avoiding the US.
In behavioral pharmacology, the rat CAR model is commonly used as a preclinical test for antipsychotic efficacy
(Arnt, 1982). It is generally found that rats treated with low
doses (noncataleptic) of antipsychotic drugs (APDs) fail to
acquire or perform avoidance responses to the CS, whereas
their escape responses to the US are not affected (Ader and

Clink, 1957; Wadenberg and Hicks, 1999). This selective
disruption of avoidance but not escape most likely reflects
the interactions between the characteristic pharmacological properties of antipsychotics and experimental factors
related to differences in scheduling of events and patterns of
behavioral responding (Spealman et al., 1983; Barrett, 2002;
McMillan and Katz, 2002). Regardless of the nature of this
selective disruption on avoidance responding, this feature
has been effectively used to differentiate APDs from other
classes of psychotropic drugs (e.g. anxiolytics and antidepressants, which lack this selectivity on avoidance vs. escape
responses); to predict clinical potencies of APDs (potencies in
the CAR test correlate with clinical potencies); and to identify
potential APDs (Janssen et al., 1965; Bignami, 1978; Cook and
Davidson, 1978; Kuribara and Tadokoro, 1981; Arnt, 1982;
Van der Heyden and Bradford, 1988; Shannon et al., 1999;
Wadenberg and Hicks, 1999). Therefore, understanding the
nature of APD-induced avoidance decreases may shed light
on the behavioral mechanism of antipsychotic action in the
treatment of psychosis in patients with schizophrenia.
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We recently used the CAR model based on a repeated
treatment regimen and examined the behavioral mechanisms of antipsychotic action in this model (Li et al., 2007).
We found that rats treated with haloperidol (HAL) and
tested daily for 7 consecutive days showed a progressive
across-session decline in avoidance responding, suggesting
that HAL may disrupt avoidance responding by progressively attenuating the motivational salience of the CS (Wise,
2004). We also found that HAL-treated rats tested under a
40-trial testing session showed a faster decline than those
tested under a 10-trial session, which in turn showed a faster
decline than those tested under a 3-trial session. These data,
together with our early study showing that rats previously
treated with HAL still exhibit decreased avoidance behavior in the later drug-free tests (Li et al., 2004), are suggested
to reflect the weakening effect of the drug on the motivational salience of the CS. On the basis of these findings, we
proposed that one possible mechanism by which APDs disrupt avoidance responding is to decrease the motivational
salience of the CS or incentive motivation of rats to respond
to the CS.
As the experiments described above were done primarily
by using the typical antipsychotic HAL, whether the same
behavioral mechanism is also responsible for the effects of
atypical antipsychotics, such as olanzapine (OLZ) or risperidone (RIS), has not been tested and is still unknown. Because
of the unique receptor-binding profile associated with each
APD (Kapur and Remington, 2001), it is possible that they
may work differently than HAL in the CAR model. Furthermore, subjects used in that study were normal rats, while
antipsychotics are usually used to treat patients with schizophrenia. Whether antipsychotics work in the same way in
putative rat models of schizophrenia has not been investigated. There is a possibility that these two functionally different populations might respond differently to antipsychotic treatment in the CAR model. Therefore, the primary
goal of this study was to investigate the behavioral mechanism underlying the decrease in avoidance responding effect
of OLZ and RIS in putative animal models of schizophrenia.
Specifically, we sought to determine (i) whether OLZ and
RIS, the two most widely prescribed atypical antipsychotics at the therapeutic relevant doses [approximately 65–80%
striatal D2 occupancy in rodents (Kapur et al., 2003)], produce a similar progressive across-session decline in avoidance responding in putative rat models of schizophrenia
[e.g. amphetamine (AMPH) pretreated or phencyclidine
(PCP) pretreated]; and (ii) to what extent repeated OLZ and
RIS treatment suppresses avoidance responding by attenuating motivational salience of the CS in the CAR model.
We chose AMPH-pretreated or PCP-pretreated rats as
animal models of schizophrenia because they mimic many
aspects of the illness at multiple levels, such as hyperdopaminergic (Robinson and Becker, 1986) and hypoglutamatergic activity (Jentsch and Roth, 1999), prepulse inhibition deficit (Geyer et al., 2001; Russig et al., 2003), latent inhibition
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deficit (Tenn et al., 2003), hypofrontal function and attentional set-shifting deficit (Fletcher et al., 2005; Tenn et al.,
2005), and social interaction deficit (Sams-Dodd, 1998b). To
explore the possible motivational salience attenuation mechanism, we used a modified avoidance conditioning procedure involving two types of CS (CS1 and CS2) that varied in
their salience and ability to predict the occurrence of the US.
If OLZ and RIS disrupt avoidance responding by selectively
attenuating the motivational salience of the CS, we expected
that both drugs would have a stronger disruptive effect on a
less salient CS (CS2)-elicited avoidance than a highly salient
CS (CS1)-elicited one.
Methods
Subjects
Male Sprague–Dawley rats (226-250 g upon arrival,
Charles River, Portage, Michigan, USA) were housed two
per cage, in 48.3 × 26.7 × 20.3cm transparent polycarbonate
cages under 12-h light/dark conditions (light on between
06.30 and 18.30 h). Room temperature was Maintained at 21
± 11°C with a relative humidity of 55-60%. Food and water
were freely available. Animals were allowed at least 1 week
of habituation to the animal facility before being used in
experiments. All procedures were approved by the Institutional Animal Care and Use Committee at the University of
Nebraska-Lincoln.
Avoidance conditioning apparatus
Six identical two-way shuttle boxes custom designed and
manufactured by Med Associates (St. Albans, Vermont,
USA) were used. Each box was housed in a ventilated,
sound-insulated isolation cubicle (96.52 cm wide × 35.56
cm deep × 63.5 cm high). Each box was 64 cm long, 30 cm
high (from grid floor), and 24 cm wide, and was divided
into two equal-sized compartments by a partition with an
arch style doorway (15 cm high × 9 cm wide at base). A barrier (4 cm high) was placed between the two compartments,
and therefore the rats had to jump from one compartment to
the other. The grid floor consisted of 40 stainless-steel rods
with a diameter of 0.48 cm, spaced 1.6 cm apart center to
center, through which a scrambled footshock (US, 0.8 mA;
maximum duration: 5 s) was delivered by a constant current
shock generator (Model ENV-410B) and scrambler (Model
ENV-412). Illumination was provided by two houselights
mounted at the top of each compartment. The CSs [either a
76 dB white noise (CS1) or a 85 dB 2800 Hz pure tone (CS2)]
were produced by a speaker (ENV-224 AMX) mounted on
the ceiling of the cubicle, centered above the shuttle box.
Background noise (approximately 74 dB) was provided by
a ventilation fan affixed at the top corner of each isolation
cubicle. All training and testing procedures were controlled
by Med Associates programs running on a computer.
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Locomotor activity apparatus
Sixteen activity boxes were housed in a quiet room. The
boxes were 48.3 × 26.7 × 20.3 cm transparent polycarbonate
cages, which were similar to the home cages but were each
equipped with a row of six photocell beams (7.8 cm between
two adjacent photobeams) placed 3.2 cm above the floor of
the cage. A computer detected the disruption of the photocell
beams and recorded the number of beam breaks. All experiments were run during the light cycle.
Experiment 1: Effect of repeated OLZ treatment on CS1 and
CS2 avoidance in PCP-pretreated rats
Forty-two rats were injected with PCP [n=22, 5 mg/kg
intraperitoneally (i.p.)] or vehicle (VEH) (n=20) twice daily
for 7 days. The two injections were separated by 12 h. This
PCP sensitization regimen has been widely used and is
shown to induce a decrease in prefrontal dopaminergic utilization, augmented motor activity, and various cognitive deficits (Jentsch et al., 1997; Jentsch and Taylor, 2001; Rodefer
et al., 2005; Dunn and Killcross, 2006). After a 5-day period
of withdrawal (the drug-free period), rats were habituated
to the shuttle box for 2 days (30 min/day). Rats were then
trained daily in a modified two-way avoidance conditioning
task for a total of 10 sessions. Each training session consisted
of 30 trials. Twenty trials (CS1 trials) used a 10 s 76 dB white
noise as the CS with its termination immediately followed
by the shock (0.8 mA; maximum duration: 5 s) if the rats did
not make an avoidance response; thus, it was a highly salient
and perfect predictor of the US. The remaining 10 trials (CS2
trials) used a pure tone (10 s, 2800 kHz, 85 dB) as the CS. In
half of the CS2 trials (five trials), the CS2 was followed by the
shock if the rat failed to respond to the CS2; whereas, in the
other half, it was not; thus, it was a less salient and less informative signal compared with the CS1. The 20 CS1 trials were
randomly intermixed with the 10 CS2 trials. During each
trial, if a subject moved from one compartment into the other
within the 10 s of CS presentation, the CS was immediately
terminated and the shock was prevented, and this shuttling
response was recorded as avoidance (termed CS1 avoidance
or CS2 avoidance). If the rat remained in the same compartment for more than 10 s and made a crossing upon receiving the footshock, this response was recorded as escape. If
the rat did not respond during the entire 5 s presentation of
the shock, the trial was terminated and escape failure was
recorded.
After training, 16 rats from the PCP group and 14 from the
VEH group had achieved a high level of avoidance responding (≥ 14 CS1 avoidances and at least one CS2 avoidance in
the last two training sessions). Each group was then randomly assigned to two subgroups and underwent 7 consecutive days of repeated OLZ or VEH testing. This resulted in
four experimental groups: PCP-VEH (n = 8), PCP–OLZ (n =
8), VEH-VEH (n = 7), and VEH-OLZ (n = 7). On each test
day, rats were injected with OLZ (1.0 mg/kg) or VEH (sterile
water) subcutaneously (s.c.) 1 h before testing. The same procedure used during training was used for the drug testing.
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Experiment 2: Effect of repeated OLZ treatment on CS1 and
CS2 avoidance in AMPH-pretreated rats
We adopted a widely used AMPH treatment schedule
that is shown to be effective in inducing deficits in prepulse
inhibition or latent inhibition resembling those observed in
patients with schizophrenia (Murphy et al., 2001; Pezze et al.,
2002; Russig et al., 2002; Peleg-Raibstein et al., 2006; PelegRaibstein and Feldon, 2008). Forty-two rats received three
daily i.p. injections of either d-amphetamine sulfate (n = 22,
AMPH at 1-5 mg/ml/kg) or 0.9% saline (n = 20, saline at
1 ml/kg). Injections were administered at 07.00, 13.00, and
19.00 h over a 6-day period. On day 1, the three AMPH injection doses were 1, 2, and 3 mg/kg in this escalating order. On
day 2, the first AMPH injection dose was 4.0 mg/kg, and the
remaining two were 5.0 mg/kg. From days 3-6, each AMPH
injection dose was always 5.0 mg/kg. The saline injection
volume was always 1 ml/kg.
The remainder of the experiment was similar to experiment
1. First, rats were trained to acquire avoidance responding to
the CS1 and CS2. At the end of the training phase, only 12
AMPH-treated rats and 10 saline-treated rats had reached
the training criterion (≥ 14 CS1 avoidances and at least one
CS2 avoidance in the last two training sessions). Thus, we
gave all rats one additional training session to boost their
performance. They were then randomly assigned to two subgroups and subjected to 7 days of OLZ tests. Four experimental groups were formed on the basis of pre-drug treatment (AMPH vs. VEH) and antipsychotic treatment (OLZ vs.
VEH): AMPH-VEH (n = 4), AMPH–OLZ (n = 8), VEH-VEH
(n = 4), and VEH-OLZ (n = 6). During each daily test, rats
were injected with OLZ (1.0 mg/kg) or VEH (sterile water)
s.c. 1 h before testing. The same procedure used during training was used for the drug testing.
Experiment 3: Replication study of the effect of repeated
OLZ treatment on CS1 and CS2 avoidance in AMPH-pretreated rats
In experiment 2, only 22 rats out of 42 (52%) reached the
training criterion, which was much lower compared with the
30 rats from experiment 1 (71%). Our past experience suggests that under most circumstances, approximately 70-75%
of rats trained in this task reach this criterion; thus, the lower
percentage of rats reaching the training criterion might suggest that rats in experiment 2 did not adequately represent
a valid sample of the rat population under study. Consequently, in experiment 3, we tried to replicate experiment 2
using a new batch of rats. The basic procedure was identical to that of experiment 2 except that rats were only tested
for four OLZ sessions, instead of seven, because we noticed
that after four OLZ sessions, avoidance responding generally reached a minimum. In this experiment, 28 rats out of
42 (67%) eventually reached the training criterion (≥ 14 CS1
avoidances and at least one CS2 avoidance in the last two
training sessions), and their grouping information was as follows: AMPH–VEH (n = 8), AMPH–OLZ (n = 8), VEH–VEH
(n = 7), and VEH–OLZ (n = 5).
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Experiment 4: Effect of repeated RIS and OLZ treatment on
CS1 and CS2 avoidance in PCP-pretreated and AMPH-pretreated rats
In experiment 4, we used different PCP and AMPH treatment regimens to examine effects of repeated RIS and OLZ
treatment on CS1 and CS2 avoidance in both PCP-pretreated
and AMPH-pretreated rats. This experiment was done not
only to replicate the findings from the above three experiments, but also to examine the generalization issue to ensure
that they can be extended to other PCP and AMPH models
of schizophrenia. As PCP and AMPH pretreatments were
done in the same batch of rats, this experiment also allowed
us to directly compare any possible differential effect of PCP
or AMPH pretreatment on RIS-induced and OLZ-induced
decrease in avoidance responding. Sixty rats were randomly
assigned to one of three groups (n = 20), with each rat receiving an s.c. injection of d-amphetamine sulfate (1.0-3.0 mg/
kg), PCP (3.0 mg/kg), or 0.9% saline (1.0 ml/kg) three times
per week for 3 weeks for a total of nine injections. The AMPH
dose increased from 1.0–3.0 mg/kg, at the rate of 1 mg/kg
each week. The PCP dose remained at 3.0 mg/kg throughout. This sensitization schedule for PCP and AMPH has been
used by Tenn et al. (2005) who showed that it can produce a
strong PCP and AMPH sensitization effect and that AMPH
sensitization induces prepulse inhibition and latent inhibition deficits. After 18 days withdrawal from PCP and AMPH
pretreatment, we assessed the AMPH and PCP pretreatment
effect (e.g. behavioral sensitization effect). All rats were habituated to the locomotor activity apparatus for 30 min/day for
2 consecutive days. On day 3, rats were placed in the locomotor activity apparatus for 10 min, and then they were taken
out and injected with either AMPH at 0.5 mg/kg or PCP
at 1.5 mg/kg and immediately placed back into the apparatus for another 60 min. Half of the rats from each group
(n = 10) were injected with AMPH, whereas the other half
(n = 10) were injected with PCP. Locomotor activity (number of photobeam breaks) was measured in 5 min blocks for
the entire 60-min testing session. One day later, the training
phase consisting of 10 sessions started. The basic procedure
was the same as described in the first three experiments with
one slight modification. Halfway through the training phase
(after the fifth session), we removed the eight rats which had
the lowest avoidance responses on that day (one from PCP,
five from the AMPH group, and two from the VEH group)
from further training to eliminate unnecessary pain and
stress, because they would most likely not reach the training
criterion based on our experience. On the last (10th) training
day, because of an unknown technical issue, data from eight
rats were lost, and we thus used the data from the eighth
and ninth training sessions to identify those that reached the
training criterion (≥ 14 CS1 avoidances and at least one CS2
avoidance in the last two training sessions). Forty-five rats
(75% of a total of 60 rats) were identified and were repeatedly tested daily for 7 days under either RIS or VEH. The following six experimental groups were formed: PCP-VEH (n =
8), PCP–RIS (n = 8), AMPH-VEH (n = 7), AMPH-RIS (n = 6),
VEH-VEH (n = 8), and VEH-RIS (n = 8). During each daily
test, rats received an s.c. injection of either RIS (0.33 mg/kg)
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or 0.9% saline 1 h before testing. One day after the end of the
seventh test, the previous three VEH groups were switched
to OLZ (1.0 mg/kg) and further tested for another five sessions. This add-on experiment was intended to assess further the effect of PCP and AMPH pretreatment on the effect
of OLZ.
Drugs
The injection solutions of d-amphetamine sulfate (AMPH,
Sigma-RBI, Natick, Massachusetts, USA) and phencyclidine hydrochloride (PCP; gift from the National Institute
on Drug Abuse Chemical Synthesis and Drug Supply Program and Sigma-Aldrich, St. Louis, Missouri, USA) were
obtained by mixing drugs with 0.9% saline. OLZ (Toronto
Research Chemical Inc., North York, Canada) and RIS (gift
from NIMH Chemical Synthesis and Drug Supply Program)
were dissolved in 1.5% glacial acetic acid in distilled water.
We chose OLZ at 1.0 mg/kg and RIS at 0.33 mg/kg because
they are effective in producing a progressive across-session
decrease in avoidance responding in normal rats (Li et al.,
2007), and both drugs at these doses give rise to clinically
comparable levels of striatal D2 occupancy (60-70%) (Kapur
et al., 2003).
Statistical analysis
CS1 and CS2 avoidance response data from the training
phase were expressed as mean values ± SEM and were analyzed using a factorial repeated-measures analysis of variance (ANOVA) with the between-subjects factor being ‘pretreatment’ (PCP, AMPH, or VEH) treatment condition and
the within-subject factors being the test sessions (‘session’)
and types of trials (e.g. ‘type’: CS1 avoidance or CS2 avoidance).
Each rat’s avoidance performance on each drug test session
was expressed as the percent avoidance relative to its own
value on the last training (10th) day (except in experiment 4,
where data from the 9th training day were used for all rats)
to account better for the differences in CS1 (maximum: 20 trials) and CS2 (maximum: 10) avoidances at the baseline. Data
were analyzed using a factorial repeated-measures ANOVA
with the between-subjects factors being ‘pretreatment’ (PCP,
AMPH, or VEH) and ‘drug’ treatment condition (OLZ, RIS,
or VEH) and the within-subject factors being the test sessions
(‘session’) and types of trials (e.g. ‘type’: CS1 avoidance or
CS2 avoidance). Two-group comparisons were tested using
post-hoc Tukey tests. A conventional two-tailed level of significance at the 5% level was required.
For the locomotor activity data from experiment 4, the
number of photobeam breaks was expressed as mean values
± SEM and analyzed using repeated-measures ANOVA with
the pretreatment condition (PCP, AMPH, or VEH) and the
challenge drugs (PCP or AMPH) as the between-subjects factors and the 5-min time block (‘block’) as the within-subjects
factor. Two-group comparison was done using independent
samples t-tests.
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Results
Experiment 1: Effect of repeated OLZ treatment on CS1 and
CS2 avoidance in PCP-pretreated rats
One rat from the VEH group died before the completion
of training. Its data were excluded from further analysis.
Throughout the 10 training sessions, rats from both groups
(PCP-pretreated or VEH-pretreated) showed a similar learning effect, as evidenced by the progressive increase in the
number of CS1 and CS2 avoidance responses across sessions
(data not shown). Repeated-measures ANOVA indicates that
there were significant main effects of ‘session’ [F(9,351) = 28.80,
P < 0.001] and ‘type’ [F(1,39) = 200.90, P < 0.001], but no significant main effect of ‘pretreatment’ [F(1,39) = 0.123, NS] or ‘type’
× ‘pretreatment’ and ‘session’ × ‘pretreatment’ interactions
(all P values > 0.75). The acquisition of CS1 avoidance was
faster than the acquisition of CS2 avoidance [‘type’ × ‘session’ interaction, F(9,351) = 13.01, P < 0.001], a result that was
expected from the experimental design in which only half of
the CS2 trials were followed by shock, whereas all the CS1
trials were followed by shock if the rats failed to respond.
Table 1 summarizes the mean numbers and percentages of
avoidance response to CS1 and CS2 on the last training session for rats that reached the training criterion. No significant group difference on these measures was found (all P
values > 0.05).
During the OLZ testing phase, the VEH-treated rats
maintained their training levels of CS1 and CS2 avoidance
throughout the sessions, whereas the OLZ rats showed a pro-
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gressive decline in both CS1 and CS2 avoidances. Repeatedmeasures ANOVA indicated that there were significant main
effects of ‘session’ [F(6,156) = 6.34, P < 0.001] and ‘drug’ [F(1,26) =
82.12, P < 0.001], and a significant ‘session’ × ‘drug’ interaction [F(6,156) = 5.10, P < 0.001]. In addition, it seems that OLZ
had a stronger disruptive effect on the CS2 avoidance than
CS1 avoidance as it caused a sharper decline in the CS2 avoidance than the CS1 avoidance relative to the baseline (Figure
1). Statistical analysis confirmed this observation. There was
a significant effect of ‘type’ × ‘drug’ interaction [F(1,26) = 6.65,
P < 0.02]. Pretreatment with PCP did not seem to significantly change the effect of OLZ, as there was no significant
main effect of ‘pretreatment’ [F(1,26) = 0.83, NS] and no significant interactions involving ‘pretreatment’ and other factors
(all P values > 0.37).
Experiment 2: Effect of repeated OLZ treatment on CS1 and
CS2 avoidance in AMPH-pretreated rats
Throughout the 11 training sessions, rats from both groups
(AMPH-pretreated or VEH-pretreated) showed a similar
learning effect, as evidenced by the progressive increase in
the number of CS1 and CS2 avoidance responses across sessions (data not shown). Repeated-measures ANOVA indicated that there were significant main effects of ‘session’
[F(10,400) = 19.09, P < 0.001] and ‘type’ [F(1,40) = 96.61, P < 0.001],
but no significant main effect of ‘pretreatment’ [F(1,40) = 0.170,
NS] or ‘type’ × ‘pretreatment’ and ‘session’ × ‘pretreatment’
interactions (all P values > 0.40). Once again, the acquisition of CS1 avoidance was faster than the acquisition of
CS2 avoidance [‘type’ × ‘session’ interaction, F(10,400) = 10.52,
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P < 0.001]. There were no significant group differences in the
mean numbers and percentages of CS1 and CS2 avoidances
on the last training session of the rats that reached the training criterion (all P values > 0.05, Table 1).
During the OLZ testing phase, the VEH-treated rats maintained their training levels of CS1 and CS2 avoidance throughout the sessions, whereas the OLZ rats showed a progressive
decline in both CS1 and CS2 avoidances. Repeated-measures
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ANOVA indicated that there were significant main effects of
‘session’ [F(6,108) = 8.129, P <0.001] and ‘drug’ [F(1,18) = 49.107,
P < 0.001], and a significant ‘session’ × ‘drug’ interaction
[F(6,108) = 3.91, P < 0.001]. Unlike the findings from experiment 1, OLZ did not show a stronger disruptive effect on the
CS2 avoidance than the CS1 avoidance (Figure 2), as there
was neither a significant main effect of ‘type’ [F(1,18) = 2.29,
NS], nor a significant ‘type’ ×‘drug’ interaction [F(1,18) = 1.42,
NS]. Pretreatment with AMPH did not seem to significantly
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change the effect of OLZ, as there was no significant main
effect of ‘pretreatment’ [F(1,18) = 0.656, NS] and no significant
interaction involving ‘pretreatment’ and other factors (all P
values > 0.08).
Experiment 3: Replication study of the effect of repeated
OLZ treatment on CS1 and CS2 avoidance in AMPH-pretreated rats
Similar to what was seen in experiment 2, rats from both
groups (AMPH-pretreated or VEH-pretreated) showed a

Li, He & Mead

in

B e h a v i o u r a l P h a r m a c o l o g y (2009)

learning effect throughout the 10 training sessions, as evidenced by the progressive increase in the number of CS1 and
CS2 avoidance responses across sessions (data not shown).
Repeated-measures ANOVA indicated that there were significant main effects of ‘session’ [F(9,360) = 32.48, P < 0.001] and
‘type’ [F(1,40) = 171.38, P < 0.001], but no significant main effect
of ‘pretreatment’ [F(1,40) = 0.12, NS] or ‘type’ × ‘pretreatment’ and ‘session’ × ‘pretreatment’ interactions (all P values > 0.83). Once again, the acquisition of CS1 avoidance was
faster than the acquisition of CS2 avoidance [‘type’ ×‘session’
interaction, F(9,360) = 15.03, P < 0.001]. There were no signifi-
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cant group differences in the mean numbers and percentages
of CS1 and CS2 avoidances on the last training session for
rats that reached the training criterion (all P values > 0.05,
Table 1).
During the OLZ testing phase, the VEH-treated rats maintained their training levels of CS1 and CS2 avoidance throughout the sessions, whereas the OLZ rats showed a progressive
decline in both CS1 and CS2 avoidances. Repeated-measures
ANOVA indicates that there were significant main effects of
‘session’ [F(3,72) = 5.63, P < 0.002] and ‘drug’ [F(1,24) = 121.53, P <
0.001], and a significant effect of ‘session’ × ‘drug’ interaction
[F(3,72) = 5.09, P < 0.005]. In addition, OLZ had a stronger disruptive effect on the CS2 avoidance than CS1 avoidance as it
caused a sharper decline in the CS2 avoidance than the CS1
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avoidance relative to the baseline (Figure 3). Statistical analysis confirmed this observation [‘type’ × ‘drug’ interaction:
F(1,24) = 6.85, P < 0.02]. Similar to experiment 2, pretreatment
of AMPH did not significantly change the effect of OLZ, as
there was no significant main effect of ‘pretreatment’ [F(1,24) =
0.058, NS] and no significant interaction involving ‘pretreatment’ and other factors (all P values > 0.11).
Experiment 4: Effect of repeated RIS and OLZ treatment on
CS1 and CS2 avoidance in PCP-pretreated and AMPH-pretreated rats
After 3 weeks of withdrawal from PCP and AMPH treatment, all rats were tested for locomotor activity after an acute
injection of PCP (1.5 mg/kg, s.c.) or AMPH (0.5 mg/kg, s.c.)
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for 60 min (12 5-min blocks) to assess the behavioral sensitization effect (Figure 4a and b). Repeated-measures ANOVA
with the ‘pretreatment’ condition (PCP, AMPH, or VEH)
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and the ‘challenge drugs’ (PCP or AMPH) as the betweensubjects factors and the 5-min time block (‘block’) as the
within-subjects factor indicated that there was a significant
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main effect of ‘challenge drugs’ [F(1,54) = 33.62, P < 0.001] and
a significant ‘challenge drugs’ × ‘pretreatment’ interaction
[F(2,54) = 8.64, P < 0.001]. Overall, AMPH caused a significantly
higher increase in the number of photobeam breaks than did
PCP. This effect was more pronounced in the AMPH-pretreated and VEH-pretreated rats than in the PCP-pretreated
ones. Over the 60-min testing period, there was a significant
main effect of ‘block’ [F(11,594) = 33.39, P <0.001] and significant interactions between ‘block’ and ‘pretreatment’ [F(22,594)
= 4.12, P < 0.001], ‘block’ and ‘challenge drugs’ [F(11,594) =
5.16, P < 0.001], and ‘block’, ‘pretreatment’, And ‘challenge
drugs’ [F(22,594) = 33.62, P <0.002]. Inspection of Figure 4b suggests that PCP pretreatment significantly potentiated the
effect of challenge treatment of PCP, as the PCP-pretreated
rats showed a significantly higher increase in the number of
photobeam breaks than the AMPH-pretreated or VEH-pretreated rats. However, the AMPH pretreatment effect was
less obvious, as 0.5 mg/kg dose of AMPH caused a similar level of increase in motor activity in AMPH-pretreated
and VEH-pretreated groups, an effect independent of pretreatment conditions; thus, the potential AMPH sensitization effect might be masked. For the total activity counts
(Figure 4c), two-group comparisons indicate that under the
AMPH challenge, the PCP-pretreated group showed a significantly lower increase in motor activity than the other
two groups (all P values < 0.029); whereas under the PCP
challenge, the PCP-pretreated group showed a significantly
higher increase in motor activity than the other groups (all
P values < 0.05).
Fifty-two rats finished all 10 training sessions. They
showed a similar level of learning, as evidenced by the progressive increase in the number of CS1 and CS2 avoidance
responses across sessions (data not shown). Repeated-measures ANOVA indicated that there were significant main
effects of ‘session’ [F(9,279) = 34.80, P < 0.001] and ‘type’ [F(1,31)
= 3036.12, P < 0.001] but no significant main effect of ‘pretreatment’ [F(2,31) = 0.97, NS] or ‘type’ × ‘pretreatment’ and
‘session’ × ‘pretreatment’ interactions (all P values > 0.085).
The acquisition of CS1 avoidance was faster than the acquisition of CS2 avoidance [‘type’ × ‘session’ interaction, F(1,31)
= 3036.12, P < 0.001], a result that was expected from the
experimental design in which only half of the CS2 trials
were followed by shock, whereas all the CS1 trials were followed by shock if the rats failed to respond. There were no
significant group differences in the mean numbers and percentages of CS1 and CS2 avoidances on the last training session for rats that reached the training criterion (all P values
> 0.05, Table 1).
During the RIS testing phase, the VEH-treated rats
maintained their training levels of CS1 and CS2 avoidance throughout the sessions, whereas the RIS-treated rats
showed a progressive decline in both CS1 and CS2 avoid-
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ances regardless of pretreatment (Figure 5a-c). Repeatedmeasures ANOVA indicated that there were significant
main effects of ‘session’ [F(6,234) = 2.19, P < 0.05], ‘drug’ [F(1,39)
= 48.44, P <0.001], and a significant three-way ‘session’ ×
‘drug’ × ‘pretreatment’ interaction [F(12,234) = 1.81, P < 0.05].
In addition, RIS had a stronger disruptive effect on the CS2
avoidance than CS1 avoidance. There was a significant ‘type’
× ‘drug’ interaction [F(1,39) = 6.38, P <0.02]. Pretreatment with
PCP and AMPH did not seem to alter the effect of RIS, as
there was no significant main effect of ‘pretreatment’ [F(2,39) =
0.97, NS] and no significant ‘pretreatment’ and ‘drug’ interaction [F(2,39) = 2.04, NS].
During the OLZ testing phase, rats previously tested
under VEH were switched to OLZ and further tested for
five sessions (Figure 6). Similar to results from the first three
experiments, the OLZ rats showed a progressive decline in
both CS1 and CS2 avoidances across sessions in comparison with their avoidance performance on the last VEH session. Repeated-measures ANOVA indicated that there was
a significant main effect of ‘session’ [F(4,80) = 5.05, P < 0.001].
In addition, OLZ had a stronger disruptive effect on the
CS2 avoidance than CS1 avoidance as there was a significant main effect of ‘type’ [F(1,20) = 17.46, P < 0.001]. Pretreatment with PCP or AMPH did not significantly change the
effect of OLZ, as there was no significant main effect of ‘pretreatment’ [F(2,20) = 0.94, NS] and no significant interactions
involving ‘pretreatment’ and other factors (all P values >
0.14).
Discussion
This study examined the behavioral mechanism of the
atypical antipsychotics OLZ and RIS in the CAR model in
PCP-pretreated and AMPH-pretreated rats, two widely
used putative animal models of schizophrenia. We used a
modified avoidance response task in which two different
salient CS signals were used to elicit avoidance response,
and found that both OLZ and RIS produced a progressive
decrease in avoidance responding across sessions in drug
naive, as well as PCP-pretreated and AMPH-pretreated rats,
confirming and extending our previous findings (Li et al.,
2007). More importantly, we found that OLZ and RIS preferentially disrupted a less salient CS (CS2)-elicited avoidance
to a highly salient CS (CS1)-elicited avoidance, a finding
that is consistent with the view that antipsychotics disrupt
avoidance responding primarily by selectively attenuating the motivational salience of the CS (Li et al., 2007). Furthermore, we did not find any consistent effect of PCP and
AMPH pretreatment on the decrease in avoidance responding elicited by OLZ and RIS, suggesting that behavioral
action of antipsychotics operates similarly in different populations of subjects.

96 								

Our previous study provides several pieces of evidence
suggesting that HAL at noncataleptic and clinically relevant doses (< 0.05 mg/kg, s.c, based on the striatal dopamine D2 occupancy data; (Kapur et al., 2003) disrupt avoidance responding primarily by attenuating the motivational
salience of the CS (Li et al., 2004, 2007). In other words,
HAL is suggested to decrease the ability of the CS to elicit
active motor response to terminate the CS and avoid the US
(Beninger, 1989; Berridge and Robinson, 1998). In this study,
we used a novel CAR task and asked whether or not atypical OLZ and RIS also disrupt avoidance responding by this
mechanism. In this task, we created two types of CS signals
(CS1 and CS2) that varied in their motivational salience (e.g.
ability to elicit avoidance). This was achieved by pairing the
CS1 with the US in every CS1 trial, whereas pairing the CS2
with the US in only half of the CS2 trials if the rats failed to
respond. In addition, we used more CS1 trials (20) than CS2
trials (10) in each training/testing session. That the CS2 was
rendered to be a less salient signal was reflected by the following two findings: first, at the end of training, the mean
numbers and percentages of CS2elicited avoidances (4.085.60 out of 10, or 40.8-56.0%) were much lower than CS1elicited ones (18.23-19.38 out of 20, or 91.1-96.9%) (Table 1);
and second, rats acquired CS2 avoidance at a much slower
rate than CS1 avoidance. As the sensory and motor functions required to perform CS1 and CS2 avoidances are the
same, the preferentially disruptive effect of OLZ and RIS
on CS2 avoidance over CS1 avoidance cannot be attributed
to their actions on sensory and motor functions, but rather
indicates an action on incentive motivation of rats. In the
CAR model, the ‘incentive motivation’ refers to the motivation instigated by a salient stimulus that drives organisms
to actively pursue a safe environment or situation. Thus,
HAL, OLZ, and RIS may disrupt avoidance responding by
decreasing incentive motivation of rats to respond to the
CS1 and CS2. This conceptualization of ‘incentive motivation’ is very similar to that of Salamone and Correa (2002),
who suggest that low doses of dopamine antagonists, such
as HAL, impair activational aspects of motivation, making
animals less likely to engage in instrumental responses to
obtain positive rewards. Alternatively, it is also possible that
the differential drug effects on CS1 and CS2 avoidance may
result from the different baseline levels of avoidance. On
the last training day, the mean CS1 avoidance from all four
experiments was about 95%, whereas the mean CS2 avoidance was only 50%. This difference in avoidance responding
rate at baseline may influence the magnitude of the disruptive effects of APDs, independent of motivational salience
of CS1 and CS2. In the literature, there are many illustrations of this phenomenon that differences in scheduling of
events and patterns of behavioral responding can determine the direction and magnitude of the behavioral effects
of drugs (Dews, 1976; Spealman et al., 1983; Barrett, 2002;
McMillan and Katz, 2002; Barrett et al., 2008). For example,
it has been shown that under certain conditions, clozapine
and chlordiazepoxide can decrease or increase a lever-pressing response (presentation of food, presentation of electric
shock or termination of a stimulus associated with electric
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shock) under different schedules of reinforcement (a fixedinterval schedule or a multiple schedule with alternating
fixed-ratio and fixed-interval components) (Spealman et al.,
1983). To distinguish between these two alternative interpretations (‘‘motivational salience’’ versus ‘‘different baseline response’’), it is ideal to create a condition in which
CS1 and CS2 avoidance have equivalent baselines but different motivational saliencies or have equivalent motivational saliencies but different baselines. One way to achieve
this is to make the number of CS2-shock pairings equal to
the number of CS1-shock pairings but to maintain the percentage of CS2 and CS1 trials followed by shock at 50% and
100% respectively (i.e., the total number of CS2 trials are
twice the number of CS1 trials). Under this condition, the
baselines of CS1 and CS2 avoidance will be similar, but CS1
will still be more salient than CS2 due to the fact that it will
be paired with shock to a greater proportion of its presentations than CS2. If the motivational salience interpretation
is correct, we expect that antipsychotics would still decrease
CS2 avoidance to a greater extent than CS1 avoidance. On
the other hand, if the different baseline interpretation is correct, we expect that antipsychotics would decrease CS1 and
CS2 avoidance to a similar extent. Future work is needed to
determine the relative validity of each interpretation.
In this study, we also examined whether antipsychotics
disrupt avoidance responding in putative animal models of
schizophrenia in the same way as in normal animals. This
was done by using two widely used pharmacological models of schizophrenia, AMPH sensitization, and PCP sensitization (Robinson and Becker, 1986; Xu and Domino, 1994;
Phillips et al., 2001; Castner et al., 2005; Featherstone et al.,
2007). It is well known that repeated intermittent exposure
to psychostimulants such as AMPH and dissociative anesthetics such as PCP can induce psychotic-like disorders very
similar to psychosis observed in patients with schizophrenia (Bell, 1965; Janowsky and Risch, 1979; Javitt and Zukin,
1991). Both classes of psychotomimetic drugs also exacerbate
existing psychotic symptoms in acute patients with schizophrenia (Itil et al., 1967; Snyder, 1973; Murray, 2002). Animals
repeatedly treated with AMPH or PCP show an array of longlasting molecular, cellular, and behavioral changes similar
to those observed in patients with schizophrenia (Robinson
and Becker, 1986; Nestler, 2001; Martinez et al., 2005), such as
behavioral sensitization (Segal and Mandell, 1974; Segal et
al., 1981) and various psychological dysfunctions such as deficits in attention (Geyer et al., 2001; Tenn et al., 2005), working memory (Bruto et al., 1984; Jentsch et al., 1997; Jentsch and
Anzivino, 2004; Marrs et al., 2005), behavioral flexibility and
executive functioning (Jentsch and Taylor, 2001; Fletcher et
al., 2005), and social interaction (Sams-Dodd, 1998a; Ellenbroek and Cools, 2000). In this study, we used the AMPH
and PCP treatment regimens that are commonly used in the
literature (Jentsch et al., 1997; Jentsch and Taylor, 2001; Murphy et al., 2001; Pezze et al., 2002; Russig et al., 2002; Rodefer
et al., 2005; Dunn and Killcross, 2006; Peleg-Raibstein et al.,
2006; Peleg-Raibstein and Feldon, 2008), and found that OLZ
and RIS had a similar effect in PCP-pretreated and AMPH-
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pretreated rats compared with saline rats. This finding suggests that the behavioral mechanism of antipsychotic action
might operate in the same manner in different populations
of subjects.
One caveat concerning this conclusion is that we only
found the long-term sensitization effect with PCP, but not
with AMPH (Figure 4). This lack of strong demonstration
of AMPH sensitization effects was surprising given the
fact that a similar 3-week sensitization regimen has been
shown in other studies to be effective in inducing a longlasting locomotor sensitization and deficits in latent inhibition and prepulse inhibition (Tenn et al., 2003, 2005) and
that we did find a robust PCP sensitization effect. The apparatuses used in those studies were also identical to ours.
Although the exact cause of this difference is unknown, it is
reasonable to assume that this pretreatment schedule may
not reliably produce sensitization to AMPH. Thus, whether
antipsychotics work through a similar behavioral mechanism in AMPH-based animal models of schizophrenia is
still an open question. Further studies may be needed to
clarify this point.
This study may provide a clue on the behavioral mechanism of antipsychotic action in the treatment of schizophrenia. Kapur (2003) theorized that APDs work psychologically
by suppressing incentive learning or weakening motivational
salience so that new aberrant beliefs are less likely to form
and previously formed aberrant memories are more likely
to be extinguished. It is thought that APDs, by inhibiting
the dopamine system, may attenuate the (aberrant) reinforcing effectiveness of stimuli that the patient is experiencing.
This may lead to the almost immediate halt of the generation of new psychotic material and allows for the gradually
progressive extinction of psychotic symptoms. This theory
of action of antipsychotics is not dissimilar to the findings
from this study showing that antipsychotics disrupt avoidance responding (a behavioral proxy of ‘psychosis’) by attenuating the motivational salience of the CS.
Taken together, this study used a novel avoidance conditioning model and showed that atypical antipsychotics OLZ and
RIS disrupt avoidance responding elicited by a weak stimulus to a greater extent and at a faster rate than one elicited by
a strong stimulus. This effect is seen in normal rats as well as
in rats that were pretreated with AMPH or PCP. These findings suggest that antipsychotics may achieve their therapeutic effect by attenuating the motivational salience of stimuli.
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